BioStem Technologies, Inc. (OTCMKTS:BSEM) Short Interest Up 17.1% in December

BioStem Technologies, Inc. (OTCMKTS:BSEM) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 137,800 shares, a growth of 17.1% from the November 30th total of 117,700 shares. Based on an average daily trading volume, of 120,600 shares, the short-interest ratio is currently 1.1 days.

BioStem Technologies Stock Down 5.2 %

OTCMKTS BSEM traded down $0.83 during trading hours on Tuesday, hitting $11.99. 53,414 shares of the company were exchanged, compared to its average volume of 38,395. BioStem Technologies has a 52 week low of $4.41 and a 52 week high of $28.26. The stock has a 50-day moving average price of $15.85 and a 200 day moving average price of $12.09. The stock has a market cap of $199.63 million, a PE ratio of 17.63 and a beta of -0.62.

BioStem Technologies (OTCMKTS:BSEM) last released its earnings results on Tuesday, November 12th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.01. The company had revenue of $82.56 million for the quarter, compared to the consensus estimate of $78.22 million. As a group, sell-side analysts anticipate that BioStem Technologies will post 1.41 earnings per share for the current year.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.